anti-CD273 [B7-DC/PD-L2] (human), mAb (ANC8D12)
| Code | Size | Price |
|---|
| ANC-273-020-100ug | 100 ug | £243.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Application: Flow Cytometry
Shipping:
BI
Storage:
+4°C
Further Information
Alternate Names/Synonyms:
Programmed Death Ligand 2
EClass:
32160000
Form (Short):
liquid
Formulation:
50mM Sodium Phosphate pH 7.5, 100mM Potassium Chloride, 150mM NaCl, 0.5% Gentamicin sulfate.
Handling Advice:
Avoid freeze/thaw cycles.
Immunogen:
Recombinant human CD273.
Long Description:
Monoclonal Antibody. Isotype: Mouse IgG2akappa. Clone: ANC8D12. Applications: ELISA, FACS, FUNC (Blocking). 50mM Sodium Phosphate pH 7.5, 100mM Potassium Chloride, 150mM NaCl, 0.5% Gentamicin sulfate. CD273 (B7-DC; PD-L2) is a type I surface molecule with homology to CD80, CD86, CD274. It is expressed primarily by dendritic cells and provides a stimulatory signal to CD279 (PD-1; Programmed Cell Death 1) which has an important immunoregulatory role by downregulating the T cell response. CD273 binds to CD279 (PD-1) with a 2-6 fold higher affinity than CD274 and is an important component of immune regulation.
Package Type:
Plastic Vial
Product Description:
CD273 (B7-DC; PD-L2) is a type I surface molecule with homology to CD80, CD86, CD274. It is expressed primarily by dendritic cells and provides a stimulatory signal to CD279 (PD-1; Programmed Cell Death 1) which has an important immunoregulatory role by downregulating the T cell response. CD273 binds to CD279 (PD-1) with a 2-6 fold higher affinity than CD274 and is an important component of immune regulation.
Purity:
>95% (SDS-PAGE)
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at +4°C.
Related Products
| Product Name | Product Code | Supplier | anti-CD273 [B7-DC/PD-L2] (human), mAb (ANC8D12) (Biotin) | ANC-273-030 | Ancell | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| anti-CD273 [B7-DC/PD-L2] (human), mAb (ANC8D12) (FITC) | ANC-273-040 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD273 [B7-DC/PD-L2] (human), mAb (ANC8D12) (preservative free) | ANC-273-820 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||